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Objective: Tirofiban (Aggrastat) is a reversible, nonpeptide inhibitor of 
platelet glycoprotein II/ I I Ia receptors. We tested the hypothesis that 
tirofiban preserves platelet number and function and shortens postopera- 
tive bleeding times in baboons after cardiopulmonary bypass. Methods: 
Four groups were studied: control, n = 12; low-dose tirofiban (0.1 gg/kg per 
minute), n = 7; high-dose tirofiban (0.3 gg/kg per minute), n = 7; and bolus 
tirofiban (15 gg/kg) followed by 0.1 gg/kg per minute during cardiopulmo- 
nary bypass, n = 7. After heparin, animals were perfused for 60 minutes at 
50 ml/kg per minute and 37 ° C with a bubble oxygenator, oller pump, and 
peripheral cannulation. Hemodynamics, platelet count, platelet aggrega- 
tion to adenosine diphosphate, and release of jB-thromboglobulin were 
measured before tirofiban i fusion, before heparin, after heparin before 
bypass, after 5 and 55 minutes of bypass, after protamine, and 60 minutes 
after protamine. Template bleeding times were measured at the same times 
except during cardiopulmonary bypass and 120 and 180 minutes after 
protamine administration. Platelet glycoprotein II Ia antigen was measured 
in Triton X-100 washes (Sigma Chemical Company) of the perfusion circuit 
after bypass. Results: High-dose tirofiban completely prevents platelet loss 
during cardiopulmonary b pass./B-Thromboglobulin release and sensitiv- 
ity to adenosine diphosphate are significantly less than control at the end 
of bypass in all tirofiban groups. Template bleeding times return to 
preoperative values in both the low- and high-dose tirofiban groups 180 
minutes after protamine administration and are significantly less than 
control bleeding times at both 120 and 180 minutes after protamine. 
Surface glycoprotein II Ia antigen does not significantly differ between 
groups. Conclusion: High-dose tirofiban completely preserves platelet num- 
ber and improves platelet function during cardiopulmonary bypass in 
baboons and significantly accelerates restoration of normal template 
bleeding times after bypass. (J Thorac Cardiovasc Surg 1997;113:182-93)  
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Bl eeding remains a major problem of cardiac »perations; approximately 4% of patients re- 
quire reoperation within the first 24 hours to control 
bleeding. 1 Nonsurgical bleeding is responsible for 
50% to 65% of these return visits. In addition, all 
patients bleed substantially more than would be 
expected if cardiopulmonary b pass (CPB) were not 
used. Bleeding problems after CPB are generally 
related to heparin, fibrinolysis, platelets, or a com- 
bination of these factors; deficiency of soluble coag- 
ulation factors is a rare cause of postoperative 
bleeding. 2 Inhibitors are available to manage bleed- 
ing problems related to heparin and to circulating 
fibrinolysins. Platelets are partially activated by hep- 
arin 3, 4 and are diluted, destroyed, and altered dur- 
ing CPB because of adhesion to circuit surfaces, 
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Fig. 1. Heart rate, cardiac output, and mean arterial blood pressure (AB[') before, during, and after CPB 
for 4 groups. Circles indicate control group (group 1), triangles indicate low-dose group (group 2), squares 
indicate high-dose group (group 3), and diamonds indicate bolus plus low-dose group (group 4). Values are 
the mean _+ standard error of the mean. Analysis of variance for repeated measur,es for four groups 
(statistical significance identified at p < 0.05, for p value or F statistic by analysis of variance). *Significant 
difference (p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with 
BASELINE. tSignificant difference (p < 0.05, unpaired t test with Bonferroni correction) between each 
tirofiban group and control. 
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Table I. Hemodynamic data 
Group BASELINE TIROFIBAN HEPARIN START END 
Heart rate (beats/min) Control 109 -- 5 115 2 25 115 + 5 127 -+ 6* 122 + 7 
Low dose 101 + 6 112 -+ 8 118 _+ 7 127 - 8* 115 + 7 
High dose 104 + 3 104 + 5 115 -+ 3 133 - 11" 103 _+ 1 
Bolus + low 107 _+ 7 115 _+ 6 139 __ 5* 150 _+ 8"? 
Control 81 _+ 6 68 ± 24 75 -+ 5 69 -+ 5 74 _+ 4 
Low dose 69 -+ 5 71 ± 5 63 - 6 55 - 5"~ 63 + 5 
High dose 71 _ 7 70 -~ 5 62 _+ 4 72 -+ 3 62 _+ 3 
Bolus + low 59 --- 3t 74 _+ 4* 64 + 4 62 _+ 4 
Control 113 _+ 6 114 _+ 4 116 ___ 7 
Low dose 117 _+ 4 116 -+ 4 121 _+ 4 
High dose 112 _+ 7 108 -+ 10 117 _+ 11 
Bolus + low 126 _+ 4 129 _+ 9 
Mean BP (mm Hg) 
Cardiac output (ml/min/kg) 
Hemodynamic measurements of heart rate, mean arterial blood pressure (BP), and cardiac output. Values are the mean _+ standard error of the mean. 
ANOVA, Analysis of variance for repeated measures for four groups (statisticaI significance identified at p < 0.05, for p value or F statistic by ANOVA). 
*Significant difference (p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with BASELINE. 
tSignificant difference (p < 0.05, unpaired t test with Bonferroni correction) between tirofiban group and c ntrol. 
aggregation and activation, and removal ofdamaged 
platelets by the reticuloendothelial system. Thus, 
after CPB, deficiency in platelet numbers and func- 
tion prolongs template bleeding times and contrib- 
utes to postoperative bleeding. 
Temporary pharmacologic nhibition of platelets 
during the period of CPB is an attractive strategy for 
preserving platelet number and function. Phospho- 
diesterase inhibitors (dipyridamole) and cyclic aden- 
osine monophosphate catalysts (prostanoids) re- 
versibly inhibit platelets, and both have been used 
clinically to preserve platelet number and function. » 
However, dipyridamole given intravenously only 
partially protects platelets during CPB 5 and has a 
long half-life in plasma. The drug has not progressed 
to general use. Prostanoids, particularly iloprost 
(Berlex Laboratories, Inc.), protect platelets during 
CPB, but must be used with a vasoconstrictor to
maintain systemic blood pressure. 6 Aspirin inhibits 
cyclooxygenase and causes irreversible inhibition of 
platelet hromboxane and prostacyclin synthesis. 
The final step in platelet adhesion and aggrega- 
tion is binding fibrinogen to the activated, mem- 
brane-bound glycoprotein complex, glycoprotein 
(GP) IIb/IIIa. 7' 8 Antibodies directed against GPIIb/ 
IIIa and the disintegrin family of RGD (arginyl- 
glycyl-aspartyl)-containing peptides TM are potent 
inhibitors of these reactions. Previous studies from 
our laboratories demonstrated that four disinte- 
grins--bitistatin, echistatin, albolabrin, and flavori- 
din--protect platelets during simulated extracorpo- 
real circulation of fresh heparinized human blood by 
preventing platelet adhesion and aggregation. 12A 
single dose of bitistatin protected platelets during 12 
to 14 hours of extracorporeal membrane oxygen- 
ation in sheep. 13 
This study evaluates a novel, reversible, nonpro- 
tein platelet GPIIb/IIIa receptor inhibitor, tirofiban 
(Aggrastat, Merck Inc.). Tirofiban is a tyrosine 
derivative and has been designed as a small molec- 
ular, nonpeptide RGD mimetic recognized by the 
GPIIb/IIIa receptor complex but not by other RGD 
integrins.14, 15 The drug is nontoxic and has been 
tested in the dog and baboon, in healthy human 
volunteers, 16and in patients with coronary artery 
disease. The drug has a half-life in plasma of 1.6 
hours. 17 These studies reveal that tirofiban is effec- 
tive in inhibiting platelet aggregation, in increasing 
bleeding times, and in preventing arterial thrombus 
formation in a dose-dependent manner without 
significant drug-related adverse ffects. 
We tested the efficacy of tirofiban to preserve 
both platelet numbers and function during CPB and 
to shorten postoperative bleeding times so that 
adequate numbers of healthy platelets are vailable 
after CPB for hemostasis. 
Methods 
Juvenile baboons (Papio annubis) weighing 10 to 23 kg 
were used. The animals were divided into four groups: 
control (group 1, n = 12); low-dose tirofiban infusion (0.1 
tLg/kg per minute) during the hour before CPB and during 
60 minutes of CPB (group 2, n = 7); high-dose tirofiban 
infusion (0.3 tzg/kg per minute) before and during CPB, as 
in group 2 (group 3, n = 7); and bolus injection f 
tirofiban (15 /zg/kg) before starting CPB and low-dose 
infusion (0.1 txg/kg per minute) during CPB (group 4, n = 
7). For each CPB experiment, the baboon was placed in a 
squeeze cage and sedated with ketamine hydrochloride, 
10 mg/kg, given intramuscularly. Anesthesia was induced 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 113, Number 1 
Hirarnatsu et al. 1 8 5 
p Value F-statistic 
PROTAMINE PROTAMINE-ó0 (ANOVA) (ANOVA) 
99 -+- 3 97 _+ 4 0.0001 
98 _+ 4 96 -+ 3 0.53671 
97 _+ 1 97 -+ 1 0.32198 
124 +_ 81" 109 -+ 5t 0.000001 
66 -+ 3* 63 -+ 3* 0.002 
63 -+ 3 60 -+ 2 0.0005 
60 -+ 3 59 -+ 3 0.00967 
65 -- 4 61 _+ 2 0.00837 
114 -+ 7 100 _+ 5 0.0001 
136 _+ 4"? 107 -+ 4 0.0401 
116 _+ 11 102 --- 7 0.83242 
144 + 5t 125 - 6? 0.00004 
with thiopental sodium, 5 mg/kg, given intravenously. The 
animal was intubated, and general nesthesia was main- 
tained with inhalational isoflurane. The right or left side 
of the heck and both groins were prepared and draped 
appropriately for sterile cutdown and cannulation of 
vessels. Hemodynamic monitoring was accomplished by 
means of an arterial ine with a 22-gauge catheter placed 
in the femoral artery and a 5F thermodilution catheter 
placed via a femoral vein. After anticoagulation with 
porcine sodium heparin (300 units/kg, Elkins-Sinn, Inc., 
Cherry Hill, N.J.) a 10F to 14F Bio-Medicus (Medtronic 
Bio-Medicus, Eden Prairie, Minn.) wire-wrapped, poly- 
urethane catheter was introduced into the jugular vein 
and advanced into the right atrium. A similar, but shorter 
8F arterial catheter for reinfusion was inserted into the 
femoral artery. 
Each bypass circuit was assembled with silicone rubber 
tubing (Dow Corning Corporation, Midland, Mich.) in- 
corporating a bubble oxygenater (Bentley 5/Pediatric, 
Baxter Healthcare Corporation, Irvine, Calif.), an arterial 
filter (Intersept Pediatric, Medtronic, Inc., Anaheim, Cal- 
il.), and a roller pump (Sarns model 13400, Sarns/3M, 
Ann Arbor, Mich.). The circuit was primed with approx- 
imately 500 ml of Normosol solution (Abbott Laborato- 
fies, North Chicago, Ill.). Normothermic CPB began at a 
flow rate of 50 ml/kg per minute (approximately one half 
of the baboon's resting cardiac output), and perfusion was 
maintained for 60 minutes. In groups 2, 3, and 4, tirofiban 
was given at a constant flow rate by means of an infusion 
pump (model 55-1111, Harvard Apparatus Co., South 
Natick, Mass.) through the femoral vein. 
Seven blood samples (15 to 20 ml each) were obtained 
at baseline before tirofiban infusion (time point labeled 
baseline); after the start of tirofiban infusion in groups 1, 
2, and 3 before heparin (tirofiban); after heparin in groups 
1, 2, and 3 or after heparin and tirofiban injection in group 
4 before CPB (heparin); 5 minutes after the start of CPB 
(start); 5 minutes before CPB was stopped (end); 10 
minutes after protamine was given (3 mg/kg, Elkins-Sinn, 
Inc., Cherry Hill, N.J.) (protamine); and 60 minutes after 
time point protamine (protamine-60). 
Heart rate by electrocardiogram, systemic (systolic, 
diastolic, mean) arterial blood pressures, central venous 
pressure, pulmonary arterial pressure, and pulmonary 
capillary wedge pressure were continuously monitored. 
Intermittent thermodilution cardiac outputs were mea- 
sured before and after CPB. Blood samples were assayed 
for hematocrit value, platelet count, white blood cell 
count, platelet aggregation toadenosine diphosphate, and 
B-thromboglobulin (/3TG) release. Dilution of formed 
blood elements and plasma/3TG was corrected using the 
hematocrit value. The total amount of blood withdrawn 
was limited to less than 10% of body weight (120 to 180 
ml) for each experiment, and blood remaining in the 
peffusion circuit was reinfused at the end of CPB. The 
CPB circuit was then rinsed with 500 ml normal saline 
solution followed by 500 ml of 0.1% Triton X-100 solution 
(Sigma Chemical Company, St. Louis, Mo.). An aliquot of 
the Triton X-100 wash was taken for measurement of
surface platelet GPIIIa antigen. Plasma and Triton X-100 
wash samples were ffozen at -70°C  until analysis. At 
least 6 weeks of recovery for each baboon was allowed 
before the next experiment. 
Hematocrit and platelet count assays were performed 
on whole blood. Platelets were counted by phase micros- 
copy or by means of a Coulter Counter (model STKR, 
Coulter Electronics Inc., Hileah, Fla.) in triplicate. Plate- 
let count was corrected for hemodilution and was ex- 
pressed as a percentage of BASELINE values. Platelet 
aggregation to adenosine diphosphate was studied with a 
Payton aggregometer (model 440, Chrono-Log, Inc., Hav- 
ertown, Pa.). Platelet-rich plasma and platelet-poor 
plasma were prepared from citrated blood (10 ml with 
10% by volume of 3.8% citrate) by differential centrifu- 
gation at 150g for 10 minutes and 13,600g for 5 minutes, 
respectively. Before studies of aggregation, the platelet 
count of platelet-rich plasma was adjusted to 150,000//xl 
by dilution with platelet-poor plasma. The concentration 
of adenosine diphosphate required to produce complete 
second-wave aggregation was measured; complete sec- 
ond-wave aggregation was assumed when light transmis- 
sion was 62.5% or greater within 5 minutes. 18 Platelet 
aggregation is reported as a percentage, normalized to the 
concentration of adenosine diphosphate required to ob- 
tain full aggregation of the baseline sample and the 
percent aggregation observed at that adenosine diphos- 
phate concentration i  subsequent samples. 
Template bleeding times were measured in duplicate on 
the forearm at the same time points as blood samples 
except during CPB and also were measured 120 and 180 
minutes after PROTAMINE (time points labeled PRO- 
TAMINE-120 and PROTAMINE-180) by means of a 
blood pressure cuff inttated to 40 mm Hg. The Simplate II 
(Organon Teknika Corporation, Durham, N.C.) lancet 
was used to create reproducible skin incisions for deter- 
minations of bleeding times. 
For plasma /3TG analysis blood was withdrawn into 
centrifugation tubes containing 10% (by volume) of 3.8% 
acid-citrate-dextrose and prostaglandin E1 solution at 
0 ° C. /3TG was measured by radioimmunoassay, a9 Data 
for/3TG were corrected for hemodilution. 
For measurement of platelet GPIIIa antigen eluted in 
Triton X-100 wash, enzyme-linked immunosorbent assay 
plates were coated with a 400 nmol/L solution of eristosta- 
tin (200/xmol/well) in 0.05 mol/L carbonatefoicarbonate 
buffer (pH, 9.2) and incubated at 4°C overnight. Eris- 
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Table II. Measured blood and plasma constituents during experiments 
Group BASELINE TIROFIBAN HEPARIN START END 
Platelet count Control 100 95.4 _+ 0.5 87.4 _+ 3.7* 91.8 -- 3.0 75.9 + 5.2* 
(% of baseline) Low dose 100 94.4 _+ 2.2 85.4 + 2.6* 82.0 + 3.6"t 78.9 -+ 6.2* 
High dose 100 99.2 _+ 2.1 92.3 _+ 3.8 104.3 + 4.0t 115.9 _+ 6.0*t 
Bolus + low 100 98.5 _+ 2.3t 91.7 + 3.4 91.3 _+ 6.1 
Aggregation to Control 100 117.9 _+ 0.0 105.6 _+ 6.2 74.0 + 9.7* 81.3 + 6.4* 
ADP (% of baseline) Low dose 100 110.3 _+ 7.5 89.9 _+ 7.3 54.1 + 4.2* 56.2 _+ 1.7*t 
High dose 100 37.9 + 4.8"t 34.2 _+ 3.5"t 12.8 + 2.3"t 12.7 -+ 2.5"t 
Bolus + low 100 51.7 _+ 7.7"t 56.5 + 4.8* 60.4 _+ 6.2"t 
BTG (ng/ml, Hct. Control 15.1 -+ 7.8 19.3 +_ 0.8 24.8 + 5.3 80.2 + 15.3" 166.7 _+ 11 1" 
corrected) Low dose 31.3 -+ 2.7 26.8 + 5.0 27.5 _+ 5.7 55.8 --- 7.5 125.9 -+ 7.8"t 
High dose 24.5 -+ 4.7 36.2 _+ 3.5 36.8 _+ 3.1 34.2 + 6.9t 70.6 -+ 9.2"t 
Bolus + low 19.2 + 4.9 19.5 _+ 2.4 40.7 -+ 11.8t 127.3 + 10.8*t 
Bleeding times (min) Control 3.9 -+ 0.1 4.6 _+ 0.1 5.5 + 0.5 
Low dose 3.7 -+ 0.2 5.6 -+ 0.5 11.0 _+ 1.8*t 
High dose 4.1 -+ 0.2 10.9 -+ 1.6"t 19.5 -+ 0.3*t 
Bolus + low 3.6 -+ 0.2 17.8 _+ 0.8"t 
Hematocrit (%) Control 34.8 -+ 0.8 32.5 _+ 3.5 34.1 _+ 0.8 15.6 + 0.5* 20.8 -+ 0.8* 
Low dose 32.4 _+ 0.8t 33.0 _+ 0.8 32.3 _ 0.7 15.7 + 0.5* 20.6 + 0.8* 
High dose 35.1 -+ 0.7 34.4 _+ 0.8 33.0 -+ 0.5 16.0 -- 0.8* 20.7 _+ 0.6* 
Bolus + low 32.4 -+ 0.6t 31.9 _+ 0.3t 17.7 .+ 0.7*t 20.2 _+ 0.7* 
WBC count Control 100 104.3 _+ 2.6 116.2 _+ 4.0 102.8 + 13.3 222.5 -+ 29.7* 
(% of baseline) Low dose 100 106.8 _+ 7.7 132.0 _+ 10.1 75.2 + 7.2 248.8 +- 26.7* 
High dose 100 103.8 _+ 5.7 118.4 + 8.0 94.0 + 13.1 260.0 _+ 38.9* 
Bolus + low 100 109.5 _+ 5.9 96.1 -+ 12.8 223.4 -+ 16.4" 
(;hanges in measured blood and plasma constituents and bleeding times during the each experiment. Values are the mean + standard error of the mean.ADP, 
Adenosine diphosphate;/3TG, beta-thromboglobulin; WBC, white blood cell; ANOVA, analysis of variance for repeated measures for four groups (statistical 
significance identified at p < 0.05, for p value or F statistic by ANOVA). 
*Significant difference (p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with BASELINE. 
tSignificant difference (p < 0.05, unpaired t test with Bonferroni correction) betwee  each tirofiban group and control. 
tostatin was prepared as described earlier. 2° To block 
nonreacted surfaces, plates were incubated for 60 minutes 
at 37 ° C with 250 tzl/well phosphate-buffered saline solu- 
tion (PBS)/0.5% Tween 20 containing 5% nonfat milk. 
After being washed (three times) with PBS/Tween buffer, 
samples were added into wells in 1:2 dilution in buffer 
containing 20 nmol/L Tris-HCL (pH 7.4), 150 mmol/L 
NaC1, 2 nmol/L CaCI» 2 mmol/L MgCI» and 1% bovine 
serum albumin and were incubated for 60 minutes at 
37 ° C. Subsequently, known concentrations of purified 
GPIIb/Illa were added to the wells on the same plate to 
obtain the standard curve. The plate was washed three 
times with PBS/Tween buffer, and aliquots of 400 ng 
monoclonal antibody AP3 (recognizing GPIIIa) in PBS/ 
Tween buffer containing 3% nonfat milk were added to 
each well. Plates were incubated for 60 minutes at 37 ° C 
and then washed three times with PBS/Tween buffer. 
After washing, the binding of AP3 was detected with the 
use of alkaline phosphatase-conjugated goat antimouse 
immunoglobulin G as describedY 
Data points represent the mean -+ standard error of the 
mean of measurements. The unpaired Student's t test with 
Bonferroni correction and analysis of variance for repeated 
measures (SPSS for Windows 6.1, Chicago, Ill.) were used 
for statistical analysis of differences between groups, and the 
paired Student's t test with Bonferroni correction was used 
for analysis of differences within the groups. Differences 
were considered statistically significant at thep < 0.05 level. 
This study was approved by the University of Pennsylvania 
Committee on Animal Care and Utilization. 
Results 
Table I shows hemodynamic measurements of
heart rate, mean arterial blood pressure, and cardiac 
output. By analysis of variance, as compared with 
control at various times, mean arterial pressure was 
significantly higher in animals in groups 2, 3, and 4 
and heart rate was also significantly higher in group 
4 baboons (Fig. 1). Cardiac outputs were signifi- 
cantly higher in both low-dose tirofiban groups 
(groups 2 and 4) than in the control group. Although 
minor differences within and occasionally between 
groups were observed, hemodynamic measurements 
remained within the normal range for all doses of 
tirofiban at all sampling times. 
Changes in measured blood and plasma constitu- 
ents and bleeding times during the experiments are 
listed in Table II. In all studies dilution of the pump 
priming volume reduced hematocrit value in all 
groups similarly during perfusion. Hematocrit value 
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PROTAMINE PROTAMINE-60 PROTAMINE-120 PROTAMINE-180 p Value (ANOVA) F statistic (ANOVA) 
57.9 _+ 2.9* 62.6 + 2.9* 0.0001 
61.5 ± 4.4* 67.4 _+ 4.6* 0.97339 
81.0 ± 8.0"I" 89.1 + 6.9] 0.000001 
72.3 _+ 7.3* 79.1 _+ 5.3"t 0.00009 
72.5 ± 5.5* 74.8 _+ 3.4* 0.0001 
63.0 + 6.4* 75.3 _+ 7.2* 0.00027 
45.2 _+ 6.9"t 72.5 ± 4.9* 0.000001 
58.7 -- 6.9* 82.1 _+ 4.7* 0.000001 
49.2 _+ 5.6* 15.7 + 5.1 0.009 
60.5 + 9.9* 22.5 _+ 10.9 0.41537 
59.9 -- 15.7" 32.5 _+ 8.5 0.00379 
43.7 _+ 9.6* 15.9 + 2.2 0.00776 
13.6 -+ 1.5" 11.3 ± 1.3" 10.6 -- 1.7" 8.7 ± 1.7" 0.0001 
17.0 - 0.8* 12.0 ± 1.5" 6.8 + 0.5*t 4.9 ± 0.3"~ 0.62563 
17.3 ± 1.1" 13.5 -+ 1.3" 7.4 ± 0.6"t 5.4 ± 0.4t 0.00046 
16.2 ± 1.6" 13.7 ± 1.9" 7.9 ± 0.9* 6.5 ± 0.6 0.00172 
27.4 ± 0.6* 27.7 ± 0.6* 0.009 
26.0 ± 0.6* 26.9 ± 0.6* 0.00693 
26.6 ± 1.0" 27.1 ± 1.1" 0.43865 
25.1 ± 0.3"t 26.4 ± 0.5* 0.00552 
171.0 ± 20.9* 247.7 ± 26.9* 0.228 
182.5 ± 21.6" 263.2 ± 30.0* 0.56180 
154.5 +- 30.4 240.4 ± 38.9* 0.92351 
239.7 ± 23.7"t 332.5 -+ 32.4* 0.04976 
rose after CPB ended when blood was reinfused 
from the perfusion circuit (Fig. 2). 
Platelet counts decreased significantly during and 
after CPB in the control and both low-dose groups 
of animals (groups 1, 2, and 4). The bolus injection 
and low-dose infusion of tirofiban better preserved 
platelet counts thän the low-dose infusion alone, but 
neither dosage scheme completely prevented plate- 
let adhesion and loss as weil as high-dose tirofiban. 
High-dose tirofiban completely prevented platelet 
adhesion during CPB and also most strongly inhib- 
ited platelet function as assessed by sensitivity to 
adenosine diphosphate. As shown in Table II, plate- 
let counts and sensitivity to adenosine diphosphate 
significantly differed from control baboons during 
and after CPB in animals that received high-dose 
tirofiban. However, platelet function in group 3 did 
not return to control values until 60 minutes after 
protamine (Fig. 3). 
Tirofiban partially inhibited/3TG release, and the 
degree of inhibition was dose-related (Fig. 4). High- 
dose and bolus plus low-dose tirofiban significantly 
reduced plasma/3TG during CPB. Animals receiv- 
ing low-dose tirofiban (group 2) also had signifi- 
cantly less plasma /3TG at the end of CPB than 
control baboons. Plasma /3TG was rapidly cleared 
and concentrations returned to baseline within the 
hour after protamine administration. 
As expected, tirofiban prolonged bleeding times 
and this effect was dose-related (Fig. 5). The addi- 
tion of heparin further prolonged bleeding times 
before the start of CPB. A:fter CPB all doses of 
tirofiban hastened the return of bleeding times 
toward normal, and bleeding times in both low-dose 
and high-dose animals (groups 2 and 3) were signif- 
icantly less than control 2 and 3 hours after prota- 
mine was given. 
White blood cell count increased after CPB in all 
groups and there were no consistent differences 
between groups. Surface GPIIIa antigen washed 
from the perfusion circuit after CPB was 2.75 + 0.42 
ng/100 /xl in the control group and did not signifi- 
cantly differ between groups 2 and 3 (low dose, 
4.04 _+ 0.31 ng/100/xl; high dose, 3.14 _+ 0.40 ng/100 
/xl). Bolus plus low dose (group 4) was significantly 
(p < 0.05) less than control (0.44 +_ 0.31 ng/100/xl). 
Discussion 
The concept of "platelet anesthesia," introduced 
with the use of prostaglandin E~ in rhesus mon- 
keys, 22 postulates that complete, but reversible, in- 
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Fig. 2. Hematocrit-corrected platelet counts before, during, and after CPB for four groups. Platelet counts 
are standardized asa percentage ofBASELINE for each time point of the group. Circles indicate control 
group (group 1), triangles indicate low-dose group (group 2), squares indicate high-dose group (group 3), 
and diamonds indicate bolus plus low-dose group (group 4). Values are the mean -+ standard error of the 
mean. Analysis of variance for repeated measures for four groups (statistical significance identified at p < 
0.05, forp value or F statistic by analysis of variance). *Significant difference (p < 0.05, unpaired t test with 
Bonferroni correction) within each group as compared with BASELINE. ?Significant difference (p < 0.05, 
unpaired t test with Bonferroni correction) between each tirofiban group and control. 
hibition of platelet reactivity during CPB can pre- 
vent platelet aggregation, release, and adhesion and 
thus preserve platelet number and function for 
hemostasis after CPB ends. During CPB, platelets 
are activated by heparin 3' 4 and by contact with the 
nonendothelial cell, biomaterial surfaces of the per- 
fusion circuit. 3' 12 Inhibition of platelets during this 
portion of the operation does not adversely affect 
the operation because blood is anticoagulated and is 
conserved by means of mechanical measures. The 
key requirements for a "platelet anesthetic" are 
complete inhibition of all platelet functions just 
before heparin is given and quick and complete 
reversal of this inhibition after CPB ends and pro- 
tamine is given. 
There are many platelet inhibitors. Aspirin only 
partially inhibits platelet reactivity and is not revers- 
ible. Dipyridamole, a reversible, phosphodiesterase 
inhibitor, only partially inhibits platelets during 
CPB. » The prostanoids, particularly the prostacyclin 
analog, iloprost (Berlex Labs), incompletely inhibit 
platelet membrane receptors and are reversible, but 
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(p < 0.05, unpaired t test with Bonferroni correction) within each group as compared with BASELINE. 
tSignificant difference (p < 0.05, unpaired t test with Bonferroni correction) between each tirofiban group 
and control. 
also are such powerful vasodilators that their use is 
impractical. 6 
Disintegrins are RGD peptides that prevent fi- 
brinogen binding to platelets by reversibly inhibiting 
the platelet GPIIb/IIIa receptor complex. 1° Natural 
RGD peptides are potent, reversible inhibitors of 
platelet aggregation and cellular adhesion that are 
effective in extracorporeal perfusion systems. 12' 13 
The chimeric compound c7E3 containing a murine 
antibody fragment irreversibly inhibits the GPIIb/ 
IIIa receptor and is approved for clinical use. RGD 
peptidomimetrics and cyclic RGD are synthetic 
GPIIb/IIIa antagonists23; several of these com- 
pounds, including tirofiban, are potent, reversible, 
nontoxic inhibitors of platelet aggregation. These 
drugs effectively inhibit platelet reaetivity during 
interventional cardiology, and results of clinical 
trials show few side effects and no toxicity. 16'23 
However, in these applications prompt reversibility 
of the drug is not required and indeed is often 
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difference (p < 0.05, unpaired t test with Bonferroni correction) between each tirofiban group and control. 
undesirable until remodeling and healing of the 
vascular injury site begins. For cardiac operations, 
prompt and complete reversal of platelet inhibition 
is an absolute requirement. 
The results of these studies show that high-dose 
tirofiban prevents platelet adhesion and aggrega- 
tion, attenuates a granule release, and accelerates 
the return of normal postoperative bleeding times. 
The drug has no discernible side effects on hemo- 
dynamics, is in phase III clinical trials, and has no 
known toxicity. This drug appears to be a promising 
"platelet anesthetic" for clinical trials during cardiac 
operations. 
However, tirofiban may not be the ideal drug for 
cardiac operations. The half-lEe in plasma (1.6 
hours) 17 and lack of a mechanism to immediately 
reverse its action mean bleeding times are still 
prolonged during the critical first few hours after 
operation when most postoperative bleeding occurs. 
Furthermore, the drug does not completely inhibit 
/3TG release or surface-adsorbed GPIIIa antigen. 
Because the drug does not inhibit the platelet 
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Bonferroni correction) within each group as compared with BASELINE. ?Significant difference (p < 0.05, 
unpaired t test with Bonferroni correction) between each tirofiban group and control. 
thrombin receptor and because thrombin is formed 
and circulates during extracorporeal perfusion, 24 
platelets probably are activated even though aggre- 
gation and adhesion are inhibited. 
A combination of tirofiban with a low dose of 
iloprost, insufficient o cause vasodilatory side ef- 
fects, 2s may overcome this limitation. On the other 
hand, a shorter-acting, more rapidly metabolized 
drug may sufficiently protect platelets to produce 
normal coagulation without a synergistic inhibitor. 
Some cyclic RGD peptides have shorter half-life 
times; after an infusion of integrelin is stopped, 
bleeding times return to normal within 15 minutes. 26 
Reilly and associates 27have developed a monoclo- 
nal antibody against he cyclic RGD peptide DMP 
728 that immediately neutralizes its effect on bleed- 
ing time in dogs. The goal is to produce a normal 
bleeding time at the time protamine is given. Nev- 
ertheless, tirofiban should produce a meaningful 
decrease in postoperative bleeding after cardiac 
operations, particularly in patients who require re- 
operation or prolonged procedures. 
1 9 2 Hiramatsu et aL 
The Journal of Thoracic and 
Cardiovaseular Surgery 
January 1997 
We thank Michelle Money and Benjamin Jackson for 
their contribution to this study, Merck Research Labs Inc. 
for drugs and support for the study, and the Medtronic 
Corporation for their generous gifts of perfusion materi- 
als. AP3 was kindly provided by Dr. P. Newman, Blood 
Research Institute, Milwaukee, Wisconsin. 
REFERENCES 
1. Woodman RC, Harker LA. Bleeding complication associated 
with cardiopulmonary bypass. Blood 1990;76:1680-97. 
2. Harker LA, Malpass TW, Branson HE, Hessel EA II, 
Slichter SJ. Mechanism of abnormal bleeding in patients 
undergoing cardiopulmonary bypass: acquired transient 
platelet dysfunction associated with selective c~-granule r - 
lease. Blood 1980;56:824-34. 
3. Ellison N, Edmunds LH Jr, Colman RW. Platelet aggrega- 
tion following heparin and protamine administration. Anes- 
thesiology 1978;48:65-8. 
4. Khuri SF, Valeri CR, Loscalzo J, et al. Heparin causes 
platelet dysfunction and induces fibrinolysis before cardio- 
pulmonary bypass. Ann Thorac Surg 1995;60:1008-14. 
5. Teoh KH, Christakis GT, Weisel RD, et al. Dipyridamole 
preserved platelets and reduced blood loss after cardiopul- 
monary bypass. J Thorac Cardiovasc Surg 1988;96:332-41. 
6. Kappa JR, Fisher CA, Todd B, et al. Intraoperative manage- 
ment of patients with heparin-induced thrombocytopenia. 
Ann Thorac Surg 1990;49:714-23. 
7. Marguerie GA, Plow EF, Edgington TS. Human platelets 
possess an inducible and saturable receptor specific for 
fibrinogen. J Biol Chem 1979;254:5357-63. 
8. Hawiger J, Timmons S, Kloczewiak M, Strong DD, Doolittle 
RF. 3' and c~ chains of human fibrinogen possess ites reactive 
with human platelet receptors. Proc Natl Acad Sci U S A 
1982;79:2068-71. 
9. Gould RJ, Polokoff MA, Friedman PA, et al. Disintegrins: a 
family of integrin inhibitory proteins from viper venoms. Proc 
Soc Exp Biol Med 1990;195:168-71. 
10. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A routine 
monoclonal ntibody that completely blocks the binding of 
fibrinogen to platelets produces a thrombasthenic-like state 
in normal platelets and binds to glycoproteins IIb and/or IIIa. 
J Clin Invest 1983;72:325-38. 
11. Huang TF, Holt JC, Lukasiewicz H, Niewiarowski S. Tri- 
gramin: alow molecular weight peptide inhibiting fibrinogen 
interaction with platelet receptors expressed on glycoprotein 
IIb-IIIa complex. J BioI Chem 1987;262:16157-63. 
12. Musial J, Niewiarowski S, Rucinski B, et al. Inhibition of 
platelet adhesion to surfaces of extracorporeal circuits by 
disintegrins: RGD-containing peptides from viper venoms. 
Circulation 1990;82:261-73. 
13. Shigeta O, Gluszko P, Downing SW, Lu W, Niewiarowski S, 
Edmunds LH Jr. Protection of platelets during long-term 
extracorporeal membrane oxygenation i  sheep with a single 
dose of a disintegrin. Circulation 1992;86(SuppI):II398-404. 
14. Egbertson MS, Chang CTC, Duggan ME, et al. Non-peptide 
fibrinogen receptor antagonists. 2. Optimization ofa tyrosine 
template as a mimic for Arg-Gly-Asp. J Med Chem 1994;37: 
2537-51. 
15. Gould RJ, Chang CTC, Lynch RJ, et al. MK-383 is a potent 
non-peptide mimic of RGD that inhibits glycoprotein IIB/ 
IIIA (abstract). Thromb Haemost 1993;69:976. 
16. Peerlinck K, de Lepeleire I, Goldberg M, et al. MK-383 
(L-700,462), a selective non-peptide platelet glycoprotein 
IIb/IIIa antagonist, is active in man. Circulation 1993;88(Pt 
1):1512-7. 
17. Barrett JS, Murphy G, Peerlinck K, et al. Pharrnacokinetics 
and pharmacodynamics of MK-383, a selective non-peptide 
platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy 
men. Clin Pharmacol Ther 1994;50:377-88. 
18. Carvalho ACA, Colman RW, Lees RS. Platelet function in 
hyperlipoproteinemia. N Engl J Med 1974;290:434-8. 
19. Rucinski B, Niewiarowski S, James P, Walz DA, Budzynski 
Z. Antiheparin proteins ecreted by human platelets; purifi- 
cation, characterization a d radioimmunoassay. Blood 1979; 
53:47-62. 
20. McLane MA, Kowalska MA, Silver L, Shattil S J, Niewiar- 
owski S. Interaction of disintegrins with the ~IIb/33 receptor 
on resting and activated human platelets. Biochem J 1994; 
301:429-36. 
21. Cook JJ, Trybulec M, Lasz EC, Khan S, Niewiarowski S. 
Binding of glycoprotein IIIa-derived peptide 217-231 to 
fibrinogen and von Willebrand factors and its inhibition by 
platelet glycoprotein IIb/IIIa complex. Biochim Biophys Acta 
1992;1119:312-21. 
22. Addonizio VP, Strauss J III, Macarak EJ, Colman RW, 
Edmunds LH Jr. Preservation of platelet number and func- 
tion with prostaglandin during total cardiopulmonary bypass 
in rhesus monkeys. Surgery 1978;83:1680-97. 
23. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa 
receptors in cardiovascular medicine. N Engl J Med 1995; 
332:1553-9. 
24. Boisclair MD, Lane DA, Philippou H, et al. Thrombin 
production, inactivation and expression during open heart 
surgery measured by assays for activation fragments including 
a new ELISA for prothrombin fragment F1+2. Thromb 
Haemost 1993;70:253-8. 
25. Bernabei A, Gikakis N, Kowalska MA, Niewiarowski S, 
Edmunds LH Jr. Iloprost and echistatin protect platelets 
during simulated extracorporeal circulation. Ann Thorac 
Surg 1995;59:149-53. 
26. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. 
Multicenter, andomized, double blind, placebo-controlled 
trial of the platelet integrin glycoprotein IIb/IIIa blocker 
integrelin i  elective coronary intervention. Circulation 1995; 
91:2151-7. 
27. Reilly TM, Mousa SA, Racanelli AL, et al. A monoclonal 
antibody that recognizes the GPIIb/IIIa antagonist DMP 728. 
Arterioscler Thromb Vasc Biol 1995;15:2195-9. 
Diseussion 
Dr. Ben P. Bidstrup (Townsville, Australia). Dr. Ed- 
munds' group is to be congratulated for their continuing 
efforts in elucidating the mechanisms of coagulation dis- 
turbance during CPB, and for their efforts to examine 
other agents that may reduce these changes. It is impor- 
tant that we make a distinction between platelet inhibition 
(as achieved by a drug such as tirofiban) and platelet 
activation. Activation means release of granule substances 
and with subsequent irreversible changes uch that these 
platelets no longer can play a role in hemostasis. Tirofiban 
may be an important agent hat will allow platelet inhibi- 
tion in the clinical setting. 
How did you arrive at the dosage regimen? You have 
described several doses. I am reminded of the troubles 
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that clinicians have had trying to achieve an appropriate 
dose of aprotinin, another agent that is effective in 
reducing postoperative bleeding. Given the half-life of 11/2 
hours of tirofiban, how do you think platelet anesthesia 
will be reversed in human beings? Surgeons, as a general 
rule, are unlikely to want to wait 2 hours for the bleeding 
time and probably bleeding, to return to normal. How did 
you measure the surface GPIIb/II Ia antigen? 
Dr. Hiramatsu. Thank you for the question. We mea- 
sured surface GPIIIa antigen in the Triton X-100 wash 
sample from rinsing the extracorporeal perfusion circuit. 
Using an enzyme-linked immunosorbent assay for sur- 
face-adsorbed GPIIIa antigen, we did not see any differ- 
ences in adsorbed GPIIIa between control and high- and 
low-dose tirofiban. 
Dr. Bidstrup. That is not actually going to show 
whether there are any changes on the surface of the 
platelet, and it may be bettet o use flow cytometry to look 
at that. You are really looking at whether the lIb/II Ia has 
been cleaved from the surface of the platelet with that 
method, aren't you? 
Dr. Edmunds. The GPIIIa antigen is an assay devel- 
oped by Dr. Niewiarowski, which measures the platelet 
receptor that is adsorbed onto the tubing. At the end of 
CPB the circuit is rinsed with saline solution and washed 
with Triton X-100 solution. The GPIIIa antigen is mea- 
sured in the Triton X-100 wash. 
The results are very interesting and became available 
about a week ago. There is much less surface-adsorbed 
GPIIIa antigen in the bolus low-dose group than in the 
other three groups--control, high dose, and low dose. We 
cannot explain this result at this point. 
Regarding the bleeding time question, tirofiban quick- 
ens the restoration of a normal bleeding time. The 
duration of a prolonged bleeding time is still longer than 
we wish, so tirofiban is not the ideal agent. We are looking 
at an agent with a half-life of about 15 minutes. 
This receptor inhibitor does not completely prevent 
platelet activation. There may be a need to add a cyclic 
adenosine monophosphate elevator in addition to a 
GPIIb/ I I Ia receptor inhibitor. Nevertheless, we believe 
we are close to developing a platelet anesthetic for 
CPB. 
Dr. James K. Kirldin (Birmingham, Ala.). Do you have 
any information about its safety or effectiveness with 
repeated exposures? Is there any tendency for tachyphy- 
laxis? 
Dr. Hirmatsu. Several animals were studied repeatedly 
without any noticeable change in results or hemodynam- 
ics. Tirofiban is not a protein and therefore is less likely to 
cause anaphylaxis. 
Dr. Edward D. Verlier (Seattle, Wash.). If there is an 
underlying ischemic-reperfusion event, is there any dan- 
ger that this drug will exacerbate the reperfusion injury 
with this number of platelets? 
Dr. Hiramatsu. We don't have an answer for your 
question and did not investigate the possibility in these 
studies. 
